Abstract
The U.S. oversight system for genetically engineered organisms (GEOs) was evaluated to develop hypotheses and derive lessons for oversight of other emerging technologies, such as nanotechnology. Evaluation was based upon quantitative expert elicitation, semi-standardized interviews, and historical literature analysis. Through an interdisciplinary policy analysis approach, blending legal, ethical, risk analysis, and policy sciences viewpoints, criteria were used to identify strengths and weaknesses of GEOs oversight and explore correlations among its attributes and outcomes. From the three sources of data, hypotheses and broader conclusions for oversight were developed. Our analysis suggests several lessons for oversight of emerging technologies: the importance of reducing complexity and uncertainty in oversight for minimizing financial burdens on small product developers; consolidating multi-agency jurisdictions to avoid gaps and redundancies in safety reviews; consumer benefits for advancing acceptance of GEO products; rigorous and independent pre- and post-market assessment for environmental safety; early public input and transparency for ensuring public confidence; and the positive role of public input in system development,...Continue Reading
References
Jan 1, 1990·International Journal of Technology Assessment in Health Care·M F Drummond
Apr 17, 1987·Science·P Slovic
Aug 1, 1987·American Journal of Diseases of Children
Sep 6, 2000·Nature Biotechnology·S H Priest
Jan 1, 1994·Science, Technology & Human Values·Isaac Rabino
Jul 26, 1974·Science·Paul et Berg
Jan 26, 2002·Science·Jikun HuangQinfang Wang
Feb 13, 2002·Oncogene·A LasorellaA Iavarone
Mar 2, 2002·Applied Occupational and Environmental Hygiene
Apr 9, 2004·Transgenic Research·Gregory Jaffe
Jul 15, 2004·Kennedy Institute of Ethics Journal·LeRoy Walters
Apr 9, 2005·Nature Biotechnology·Kent J BradfordSteven H Strauss
Jun 24, 2005·Science As Culture·John Abraham
Feb 24, 2006·Risk Analysis : an Official Publication of the Society for Risk Analysis·I LinkovA Meyer
May 18, 1990·Science·S Jasanoff
Sep 18, 2007·Epilepsia·Anne T Berg
Jul 18, 2008·Risk Analysis : an Official Publication of the Society for Risk Analysis·Rick L WilliamsAbraham J Tobia
Jul 18, 2008·Risk Analysis : an Official Publication of the Society for Risk Analysis·Jennifer KuzmaSusan M Wolf
Citations
Dec 20, 2011·Pharmacogenomics·John Hudson
Sep 29, 2011·Drug Discovery Today·John Hudson, Marta Orviska
Aug 13, 2011·EMBO Reports·Jennifer Kuzma, Adam Kokotovich
Aug 21, 2010·Risk Analysis : an Official Publication of the Society for Risk Analysis·Jennifer Kuzma, Susanna Priest
Feb 4, 2010·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Jordan ParadiseGurumurthy Ramachandran
Feb 4, 2010·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Linda F Hogle
Feb 4, 2010·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Kristen C NelsonMichael J Banker
Feb 4, 2010·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Robbin Johnson
Feb 4, 2010·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Susan Bartlett Foote
Jun 1, 2011·Medicine, Health Care, and Philosophy·Jennifer Kuzma, Aliya Kuzhabekova